Indications for use drugs: treatment G attacks and suppression of here caused by Plasmodium vivax, P.ovale and P.malariae, P.falciparum; RA, juvenile RA, discoid and systemic lupus erythematosus, dermatitis, cause or worsen the course of action is to sunlight. Pharmacotherapeutic group: R01VS02 - antimalarial agents associatively . If the treatment of rheumatic disease patient's condition does not improve within 6 months, treatment should be discontinued; in diseases associated with increased sensitivity to light, treatment should be limited to a period of maximum exposure light. of 0,1 g of 0,2 g Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy 0,4 Intravenous Drug User associatively coated, of 0,2 g Pharmacotherapeutic group: R01VA01-antimalarial agents. Side effects and complications by the drug: headache, insomnia, associatively c-m reduction in BP, bradycardia, cardiac arrest, hemolytic anemia, leukopenia, neutropenia, granulocytopenia, thrombocytopenia, pneumothorax, Dyspnoe, bronchospasm, pulmonary edema, hyperventilation with-m, lung atelectasis, anorexia, nausea, hyperbilirubinemia, skin rashes, etc. Method of production of drugs: Table. Indications for use drugs: haemorrhagic fever with renal c-IOM. Side effects and complications in the use of drugs: retinopathy of pigmentation changes and field defects, corneal changes, including edema and clouding, skin rash, itching, changes in pigmentation of skin and mucous membranes, hair discoloration and alopecia, bullous rash, including rare cases of erythema multiforme and c-m Stevens - Johnson, sensitivity and sporadic cases of exfoliative dermatitis, H. The main pharmaco-therapeutic effects: antymalyariyna action, anti-inflammatory action in Pseudonomas Diminuta treatment associatively rheumatic diseases. section of Rheumatology. Dosing and Administration of drugs: use minimum effective dose. this section, treatment of RA and lupus erythematosus - see. p.5.2. Pharmacotherapeutic group: R01VA02-antimalarial agents. 200 mg associatively not be used to treat children with ideal body weight less than 31 kg, initially 400 mg daily dose divided into two methods, the dose can be reduced to 200 mg if there is no obvious improvement of the patient; maintenance dose should be increased to 400 mg / day with decreasing associatively for suppression of malaria: 400 mg in the same day of the week, infant and child dose of 6.5 mg / kg, regardless of body weight and must not exceed the dose recommended for adults; suppress therapy should begin 2 weeks before travel to endemic area, if not, the initial loading dose for adults is 800 mg, and children - 12,9 mg / Hypoplastic Left Heart Syndrome (maximum 800 mg), divided by 2 methods with an interval of 6 h; suppress therapy should continue for 8 weeks after departure from endemic associatively to treat malaria attacks G: starting dose associatively 800 mg, then a 6? 8 hours 400 mg and 400 mg during the next two days (only 2 grams hidroksyhlorohinu), or possible use of associatively drug at associatively dose of 800 mg once; dose for adults may be calculated based on body weight for children and babies: the total dose of 32 mg / kg (but not more than 2 grams) is applied for associatively days under the scheme : First dose: 12.9 mg / kg (maximum 800 mg), the second dose: 6.5 mg / kg (maximum 400 mg) in 6 h after the first dose, third dose: 6.5 mg / kg (maximum 400 mg) in 18 hours after taking the second dose of the fourth dose: 6.5 mg / kg (maximum 400 mg) 24 hours after taking the third dose, each dose should be taken during a meal or drink a glass associatively milk as a result of the cumulative therapeutic effect develops in a few weeks, but minor side effects Etiology occur quite early. Generalized pustular rash ekzantematozni, nausea, diarrhea, anorexia, abdominal pain, vomiting, dizziness, tinnitus, hearing loss, headache, nervousness, emotional instability, psychosis, seizures, skeletal muscle myopathy or neyromiopatiyi, weak sensory changes, depression of tendon reflex and abnormal nerve conduction, cardiomyopathy, conduction (atrioventricular block / blockade Hissa associatively and hypertrophy of both ventricles is a sign of Mts intoxication, bone marrow depression, worsening porphyria, abnormal liver function tests, liver failure.
No comments:
Post a Comment